mTOR-understanding the clinical effects.

Details

Serval ID
serval:BIB_26D046EC5F82
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
mTOR-understanding the clinical effects.
Journal
Transplantation Proceedings
Author(s)
Contreras A.G., Dormond O., Edelbauer M., Calzadilla K., Hoerning A., Pal S., Briscoe D.M.
ISSN
0041-1345, 0041-1345[linking]
Publication state
Published
Issued date
2008
Volume
40
Number
10 Suppl.
Pages
S9-S12
Language
english
Notes
Publication types: Journal Article ; Review
Abstract
The target of rapamycin (TOR) is a highly conserved serine/threonine kinase that controls cell growth and metabolism in response to nutrients, growth factors, cellular energy, and stress. The TOR kinase, which was originally discovered in yeast, is also expressed in human cells as mammalian TOR (mTOR). In this review, we focus on how mTOR-inducible signals function in cell protection and cell survival of effector and regulatory T cells as well as its role in endothelial cell biology. We evaluate how signaling is important for vascular endothelial cell growth, survival, and proliferation; and we consider how the function of mTOR in endothelial cells may be clinically important in the rejection process. Understanding the biology of mTOR allows clinicians to use mTOR inhibitors optimally as therapeutics following solid organ transplantation.
Keywords
1-Phosphatidylinositol 3-Kinase/physiology, Animals, Graft Rejection/pathology, Graft Rejection/physiopathology, Humans, Inflammation/physiopathology, Mammals, Neovascularization, Pathologic/physiopathology, Protein Kinases/physiology, Signal Transduction, Transplantation, Homologous/pathology, Vascular Endothelial Growth Factor A/physiology
Pubmed
Create date
17/02/2010 10:16
Last modification date
20/08/2019 13:05
Usage data